Table 2 Patient characteristics at admission and univariate analysis of risk factors associated with mortality
From: Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia
Variable | Survival patients n=103(75%) | Dead patients n=36(25%) | p value |
|---|---|---|---|
Age in years, median [IQR] | 46 [39–57] | 52 [40–65] | 0.15 |
Males, n (%) | 61 (59.2) | 18 (50) | 0.34 |
SAPS II, median [IQR] | 31 [23–41] | 35 [30–51] | 0.01 |
Underlying disease, n (%) | |||
Hematological malignancy | 68 (66.0) | 16 (44.4) | |
Solid organ transplantation or immunological disease or cancer | 35 (33.9) | 20 (55.5) | 0.02 |
PCP prophylaxis, n (%) | 4 (3.8) | 1 (2.7) | 0.76 |
Steroids before admission, n (%) | 53 (51.4) | 21 (58.3) | 0.48 |
Symptom duration in days, median [IQR] | 7 [3-13] | 7 [3-15] | 0.71 |
Co infection at admission | 20 (19.4) | 8 (22.2) | 0.66 |
P / F ratio at admission, median [IQR] | 173 [96-268] | 110 [86–197] | 0.04 |
Mechanical ventilation, n (%) | |||
None | 53 (51.4) | 2 (0.5) | |
NIV | 25 (24.2) | 1 (0.2) | <0.001 |
NIV and MV | 25 (24.2) | 33 (91.6) | |
Shock during ICU stay, n (%) | 19 (18.4) | 26(72.2) | <0.001 |
ICU acquired infection | 14 (13.5) | 17 (47.2) | <0.0001 |
Steroids in the ICU, n (%) | |||
No Steroid | 33 (32.0) | 12 (33.3) | |
Low Dose Steroid | 19 (18.4) | 3 (8.3) | 0.60 |
High Dose Steroids | 51 (49.5) | 21 (58.3) |